A Study for Optimization of 6% Hydroxyethyl Starch Based Indocyanine Green Near-infrared Fluorescence Navigated Sentinel Lymph Node Biopsy for Breast Cancer Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yung-Chun Hsieh, MD
- Phone Number: +886-972322925
- Email: abitzsong@gmail.com
Study Contact Backup
- Name: Yang-Hsiang Chan, PhD
- Phone Number: +886-966626689
- Email: yhchan@nycu.edu.tw
Study Locations
-
-
HsinChu County
-
Zhubei, HsinChu County, Taiwan, 302
- Recruiting
- National Taiwan University Hospital Hsin-Chu Branch BioMedical Park Hospital
-
Contact:
- Yung-Chun Hsieh, MD
- Phone Number: +886-972322925
- Email: abitzsong@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Breast cancer, adults
Exclusion Criteria:
- Patient aged < 20 years old
- Primary lesion without indication of sentinel lymph node biopsy in current guidelines (Low-risk ductal carcinoma in situ or metastatic breast cancer)
- Patient who is allergic to primary tracers (including Tc99m and blue dye)
- Patient who is allergic to indocyanine green
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Voluven diluted indocyanine green
This arm participants uses Voluven diluted ICG for sentinel lymph node mapping.
|
Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation.
The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
|
|
Active Comparator: Distilled-water diluted indocyanine green
This arm participants uses Distilled-water diluted ICG for sentinel lymph node mapping.
|
Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation.
The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Signal-to-background ratio (SBR)
Time Frame: through study completion, an average of 1 year
|
Evaluates the SBR of the near-infrared fluorescence between the retrieved sentinel lymph nodes and the background.
|
through study completion, an average of 1 year
|
|
Penetration depth
Time Frame: through study completion, an average of 1 year
|
Evaluates the depth of the deepest visualized subcutaneous lymphatics in the breast
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sentinel lymph nodes pathology
Time Frame: through study completion, an average of 1 year
|
The positivity and number of retrieved sentinel lymph nodes at definitive pathology report.
|
through study completion, an average of 1 year
|
|
Time to total visualization of breast subcutaneous lymphatics
Time Frame: through study completion, an average of 1 year
|
The time from injection of indocyanine green to total visualization of breast subcutaneous lymphatics
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Yung-Chun Hsieh, MD, National Taiwan University Hospital Hsin-Chu Branch
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 111-009-F
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.